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Ameliorative effectAim: Apelin, an adipocyte-derived factor, exhibited a number of cardioprotective properties; however, its
effect in diabetes which is a major risk factor for cardiovascular disease (CVD) needs to be further studied.
So this work was designed to evaluate the effect of apelin on diabetes and its associated cardiac hyper-
trophy with its possible underlying protective mechanisms.
Experimental protocol: Thirty male adult Wistar rats were categorized into three groups, 10 rats each, nor-
mal control group: received standard food and water regime. Diabetic control group: received streptozo-
tocin (STZ) at a dose of (55 mg/kg, i.p., once) dissolved in citrate buffer (pH 4.5). Apelin-13 treated
diabetic group: STZ diabetic rats received an intra peritoneal injection of apelin-13 at a dose of
(100 nmol/kg/day), and given daily for 8 weeks. at the end of the experiment, oral glucose tolerance test
(OGTT) was assayed, then rats were sacrificed and serum glucose, insulin, triglyceride (TG), total choles-
terol, high density lipoprotein (HDL) cholesterol, serum lactate dehydrogenase (LDH) and serum creatine
kinase – MB (CK-MB) were measured, together with cardiac hypertrophy index (CHI), left ventricular
hypertrophy index (LVHI) and left ventricular protein and collagen content levels. Myocardial superoxide
dismutase (SOD), catalase, reduced glutathione (GSH) and malondialdehyde (MDA) were determined in
the myocardial tissue of experimental rats.
Results: Treatment with apelin-13 improved hyperglycemia and hyperlipidemia, and significantly pro-
tected against STZ-induced structural alterations in cardiac tissue, it also produced a significant reduction
in MDA while it elevated the level of antioxidant enzymes in hearts of diabetic rats.
Conclusion: This study suggested that apelin can ameliorate diabetes and its associated myocardial
hypertrophy through mainly its anti diabetic, anti hyperlipidemic and anti oxidative stress properities.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus (DM) is a group of metabolic diseases caused
by a complex interaction of genetic, immunological and environ-
mental factors. DM is very common and it is a prime risk factor
for CVD, including diabetic cardiomyopathy.1
Diabetic cardiomyopathy has been defined as a ventricular dys-
function that occurs in diabetic patients independent of a recog-
nized cause, such as coronary artery disease or hypertension.2
The hallmark characteristic of diabetic cardiomyopathy is a sub-
clinical phase associated with cellular structural abnormalities
including cardiomyocyte hypertrophy, cardiac inflammation,
fibrosis and increased apoptosis which lead initially to diastolicdysfunction, later to systolic dysfunction and eventually to heart
failure.3
The pathophysiology of the link between diabetes and CVD is
complex and multifactorial, though unclear.4 However, the occur-
rence of hyperglycemia, hyperlipidemia, and oxidative stress in
diabetes has been extensively documented, and is implicated in
the pathogenesis of various cardiovascular complications including
cardiomyopathy.5 Thus, among the various therapeutic strategies,
antihyperglycemic, antihyperlipidemic, and antioxidant agents
can be useful in the prevention of cardiomyopathy in STZ induced
diabetes.6
Apelin, a small regulatory peptide, had been identified as the
endogenous ligand of the human orphan G protein coupled recep-
tor (GPCR) which is a receptor structurally related to the angioten-
sin II (ANG II) receptor AT1 but does not bind to angiotensin II, thus
it was previously designated as an ‘‘orphan” GPCR, having no
known ligand, and was named APJ.7 Later, it was identified that
apelin is the endogenous ligand for this receptor, thus The
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APJ is now apelin receptor (APLNR).8
Apelin is synthesized as a 77 amino acid pre-pro-peptide that
can be cleaved into fragments of different sizes that activate
APLNR, with apelin-13 is the final active product, being the most
potent isoform and more resistant to enzymatic cleavage.9 Apelin
is secreted mainly from white adipose tissue, however it can also
be expressed in different tissues as kidney, heart, lung and many
areas in the brain.10
Apelin peptides have been shown to affect many biological
functions in mammals including neuroendocrine, cardiovascular,
and immune systems and it can act via autocrine, paracrine, endo-
crine, and exocrine signaling.11
In recent years, apelin have been studied for its anti-obesity and
anti diabetic properties and it was recorded that apelin-13 may
have beneficial effects in metabolic disorders and its associated
complications.7
Acute intravenous injection of apelin had been shown to pro-
duce a powerful glucose-lowering effect associated with improved
glucose tolerance in high fat fed mice which were glucose intoler-
ant or frankly diabetic,12 also chronic treatment with apelin in
obesity-induced type II diabetic model improved hyperglycemia,
and insulin sensitivity but it was associated with elevated levels
of TG.10 Furthermore, it was recorded that there was a negative
correlation between apelin blood levels and glycosylated hemoglo-
bin (HbA1c) levels in diabetic patients, this indicated that higher
apelin levels were associated with lower HbA1c levels and better
glucose control, but this was only significant for type II diabetic
patient.13
In type I diabetes, the effect of apelin is markedly questionable.
Early studies recorded that the increased circulating level of apelin
in children with type I DM had no significant relation with glucose,
lipids, adiponectin levels, and insulin sensitivity,14 however, it had
been shown recently that apelin had a hypoglycemic effect and
could improve pancreatic beta cell function and lower the serum
triglycerides in type I diabetic model.10 Thus apelin’s role in glu-
cose and lipid homeostasis in type I diabetes needed further
investigations.
Furthermore, It had been shown that dysregulation of the apelin/
APLNR system may be involved in the predisposition of cardiovas-
cular diseases, and enhancing apelin action may have important
therapeutic effects, especially that some studies recorded decreased
serum level of apelin in cardiovascular diseases.15 also, apelin
proved its cardioprotective effect in different animal models, as in
cardiac ischemia reperfusion injury,16,17 isoproterenol-induced car-
diotoxicity18 and heart failure models,19 however its effect in dia-
betic cardiomyopathy is still needed to be further highlighted.
Thus, I extended this current study to investigate the anti dia-
betic and cardioprotective effects of apelin in STZ induced diabetic
rat model, delineating its different mechanisms of action in ame-
liorating the course of this disease progression.2. Material and methods
2.1. Animals and experimental design
This study was carried out on thirty male adult Wistar rats
weighing about 200–250 g. The rats were housed, four per cage,
under standard laboratory conditions at room temperature
(24 ± 2 C), and had free access to water and food. The rats were
fasted during the night before the experiment. All animal experi-
ments were undertaken with the approval of Ethical Animal
Research Committee of Tanta University.
The rats were randomly divided into three groups (10 rats
each).2.2. Normal control group
Rats were maintained on standard food and water regime.
2.3. Diabetic control group
An experimental model of diabetes was induced by intra peri-
toneal injection of STZ (55 mg/kg body weight) (Sigma–Aldrich
Chemical, Steinheim, Germany) dissolved in Na citrate solution
adjusted at pH 4.5, The control animals were injected with equal
volume of vehicle.20
STZ is anti microbial agent with a selective cytotoxicity to pan-
creatic b-cells that has the ability to induce a specific necrosis and
destruction of the pancreatic b-cells and thus it is the first choice
for diabetes induction in animals.21 This cytotoxicity to b-cells is
mediated through DNA break, nitric oxide production and Free rad-
ical generation.22
Because of streptozotocin’s ability to induce fatal hypoglycemia
as a result of massive pancreatic insulin release, the rats were pro-
vided with 10% glucose solution after 6 h of STZ administration for
the next 48 h to prevent hypoglycemia. Rats with diabetes (blood
glucose >200 mg/dl) were selected for this experiment.23
2.4. Apelin-13 treated diabetic group
Intraperitoneal injection of apelin-13 (Apelin, Phoenix Pharma-
ceutical, Belmont, CA, USA), was given at a dose of (100 nmol/kg/-
day) dissolved in saline and treatment was started after 3 days of
STZ injection, furthermore control diabetic group was injected
daily with saline via the intraperitoneal (IP) route.24
Weekly body weight gain was measured and at the end of the
experiment (8 weeks) from induction of diabetes, the following
parameters were determined.
2.5. Oral glucose tolerance test
The animals were subjected to oral glucose tolerance test
(OGTT).25 To perform OGTT, the animals were fasted at least 5 h
after the last meal, then they were orally administered with 1.5 g/
kg glucose and blood samples were collected from the tail vein
under light ether anesthesia before, and at intervals of 0 min and
30, 60 and 120 min after oral glucose administration. Samples were
analyzed for glucose and insulin as mentioned above. Plotting the
glucose concentration versus time gives a curve showing rise and
fall in glucose and insulin levels with time and results are expressed
as integrated area under the curve (AUC) for glucose and insulin.
AUC glucose and insulin levels were calculated using the trape-
zoidal method which depends on an interpolation between data
points of glucose and insulin levels measured during OGTT. For a
given time interval (t1–t2), the AUC can be calculated as follows:
AUC ¼ ðC1þ C2Þ=2 ðt2 t1Þ½26
In essence, the first two terms (C1 + C2) calculate the average
concentration over the time interval, while the last piece (t1–t2)
is the duration of time. So this method takes the average concen-
tration of glucose and insulin and applies it to the entire time inter-
val, sum of all the intervals together, gives the total AUC.27
2.6. Blood sampling and biochemical analysis
The rats were sacrificed by cervical decapitation and overnight
fasting blood samples (8 ml/rat) were taken, and allowed to clot for
2 h at room temperature before centrifugation for 20 min at
approximately 5000 rpm28 was done. The separated serum was
stored at 20 C till the time of measurement. Repeated freezing
and thawing were avoided.
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parameters:
(1) Serum glucose level:
Spectrophotometric determination of serum glucose level was
assayed according to Randox kit manufacturer’s guidelines
depending on glucose oxidase method.29
(2) Serum insulin level:
Serum insulin levels were measured using insulin ELISA kits
which include an enzyme immunoassay for the quantitative deter-
mination of insulin in sera of rats according to the manufacturer
instructions (American Diagnostica Inc., South San Francisco, CA,
USA).
(3) Serum TG level:
A peroxidase-coupled method based on30 was used for colori-
metric determination of serum triglycerides using TG assay kit
(Cayman Chemical, USA).
(4) Serum total cholesterol and HDL cholesterol level:
According to the method of,29 serum total cholesterol and HDL
cholesterol levels were determined spectrophotometrically, using
enzymatic colorimetric BioMed assay kits.
2.7. Serum cardiac enzymes assay
Serum LDH and CK-MB were measured by a quantitative sand-
wich enzyme immunoassay technique using their respective kits
(Biosource, International, Camarillo, California, USA) and all
instructions of the manufacturer were followed.
2.8. Cardiac and left ventricular hypertrophy indicies
The hearts of the experimental animals were isolated and
weight of the hearts were noted down to calculate the index of car-
diac hypertrophy as indicated by heart weight to body weight
(HW/BW) and wet left ventricular weight to body weight (LV/
BW) to calculate the index of left ventricular hypertrophy.1
2.9. Tissue homogenate preparation
Snap-frozen hearts were thawed and were dissected, left ventri-
cles (LV) from freshly excised hearts were weighed, minced and
homogenized in 80 mM Tris–HCl (pH 6.8) The homogenate was
used to determine LV protein and collagen contents together with
oxidative stress related markers.
2.10. Assesment of LV protein content
The tissue homogenate was centrifuged at 800g for 10 min31
and the clear supernatant was used to estimate total protein con-
tent using a detergent compatible kit (DC protein assay, BioRad)
according to the method of32 which is based on the reaction of pro-
tein with an alkaline copper tartrate solution and folin reagent
given a characteristic blue colour with absorbance at 750 nm.
2.11. Left ventricular collagen content assay
The left ventricular soluble collagen concentration was mea-
sured spectrophotometrically by a technique based on Sirius Red
binding to collagen33 using a commercially available kit (Sircol col-lagen assay, Biocolor, Westbury, NY, USA) according to manufac-
turers’ guidelines.
Sircol collagen assay depend on binding of sircol dye with colla-
gen by incubation for 30 min on a shaker at room temperature,
then the collagen-bound dye is recovered by centrifugation, colla-
gen is eluted with alkali, and measured using a spectrophotometer
at 540 nm.
2.12. Oxidative stress-related markers assay
The clear supernatant of LV homogenate was used for assess-
ment of antioxidant enzyme levels as SOD, catalase and GSH
together with amount of lipid peroxides that is indicated by
MDA level. SOD was determined according to the method of Misra
and Fridovich.34 Catalase was assessed by the method of Aebi.35
While GSH was measured as described by Moron et al.36 Malondi-
aldehyde (MDA) formation was measured according to the study of
Slater and Sawyer.37
3. Statistical analysis
Values are expressed as mean ± standard deviation (SD). The
results were analyzed using one-way factorial analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test using
Graph Pad Instat, 32 bit for win 95/NT (Version 3.05). The value
of P < 0.05 was considered as statistically significant.
4. Results
4.1. Effect of apelin treatment on biochemical parameters Table 1
The results of this study revealed that STZ- induced diabetes
was associated with a significant hyperglycemia, hypo insulinemia
and impaired OGTT (Fig. 1) indicated by a significant increase in
AUCglucose and a significant decrease in AUC insulin in diabetic con-
trol group when compared with that of the normal control one.
Treatment with apelin-13 at a dose of (100 nmol/kg/day) for
8 weeks significantly decreased the elevated levels of serum glu-
cose and AUCglucose, on the other hand there was insignificant dif-
ference in serum insulin and AUCinsulin levels in treated diabetic
group compared to diabetic control one.
Regarding the serum lipids, STZ-diabetic rats were found to
exhibit a significant increase in TG and cholesterol levels with a
significant decrease in HDL cholesterol levels comparable to nor-
mal control rats. Apelin treatment significantly lowered the ele-
vated level of TG and cholesterol and significantly increased HDL
cholesterol levels in treated diabetic group compared to diabetic
control one.
4.2. Effect of apelin treatment on serum LDH and CK–MB Table 2
It is obvious from the results of this work that STZ injection pro-
duced a significant increase in serum level of LDH and CK-MB in
diabetic control group compared to normal control one. Apelin
treatment significantly attenuated the increased serum level of
these enzymes in treated diabetic group compared to diabetic
control one.
4.3. Effect of apelin treatment on cardiac and left ventricular
hypertrophy indicies
The results of this work showed that both cardiac and left ven-
tricular hypertrophy indicies were significantly higher in diabetic
control group compared to normal control one which were signif-
icantly reduced under apelin treatment (Figs. 2 and 3).
Fig. 1. Effect of apelin-13 (100 nmol/kg/day) on serum glucose and insulin levels during OGTT in experimental animals after 8 weeks treatment. NC = normal control group;
DC = Diabetic control group; AD = Apelin-13 treated diabetic group.
Table 1
Effect of apelin-13 (100 nmol/kg/day) on biochemical parameters in experimental







Body weight (g) 215 ± 7.7 166 ± 5.7a 189 ± 9.2b
Serum glucose (mg/dl) 106.1 ± 9.66 303.4 ± 16.30a 188.6 ± 14.01b
Serum insulin level (mU/ml) 49.5 ± 4.95 25.7 ± 2.75a 27.1 ± 1.66
AUCglucose
(mg/dl/min)  103
14.55 ± 1.64 41.85 ± 3.35a 28.50 ± 2.76b
AUCinsulin
(mU/ml/min)  103
6.36 ± 0.49 3.55 ± 0.31a 3.66 ± 0.37
Serum triglyceride (mg/dl) 80.9 ± 7.75 190.4 ± 10.97a 147.1 ± 7.43b
Serum cholesterol level
(mg/dl)
84.2 ± 6.40 124.5 ± 6.34a 103.5 ± 4.69b
HDL cholesterol (mg/dl) 37.2 ± 3.29 24.4 ± 4.57a 33.1 ± 1.19b
All values are expressed as Mean ± SD of 10 rats in each group.
a P < 0.05 versus normal control group.
b P < 0.05 versus diabetic control group.
Table 2
Effect of apelin-13 (100 nmol/kg/day) on serum level of cardiac enzymes of







Serum LDH (U/L) 60.5 ± 5.04 239.8 ± 3.26a 138 ± 6.1b
Serum CK-MB (U/L) 39.4 ± 3.78 190 ± 4.18a 60.9 ± 3.96b
Serum lactate dehydrogenase (LDH), Serum creatine kinase-MB (CK-MB).
All values are expressed as Mean ± SD of 10 rats in each group.
a P < 0.05 versus normal control group.
b P < 0.05 versus diabetic control group.
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The present investigations revealed that the left ventricular pro-
tein and collagen content levels were found to be significantlyhigher in diabetic control rats compared to normal control ones.
Apelin significantly reduced these elevated levels in treated dia-
betic rats when compared with that of diabetic untreated ones
(Figs. 4 and 5).4.5. Effect of apelin on oxidative stress parameters in heart Table 3
Compared with normal control group, STZ induced diabetes was
associated with marked oxidative stress indicated by a significant
Fig. 2. Effect of apelin-13 (100 nmol/kg/day) on cardiac hypertrophy index in experimental animals after 8 weeks treatment NC = normal control group; DC = Diabetic control
group; AD = Apelin-13 treated diabetic group. Data are expressed as mean ± (SD). *At P < 0.05 versus normal control group, #at P < 0.05 versus control diabetic group.
Fig. 3. Effect of apelin-13 (100 nmol/kg/day) on left ventricular hypertrophy index in experimental animals after 8 weeks treatment. NC = normal control group;
DC = Diabetic control group; AD = Apelin-13 treated diabetic group. Data are expressed as mean ± (SD). *At P < 0.05 versus normal control group, #at P < 0.05 versus control
diabetic group.
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levels. Apelin treatment exhibited a marked antioxidant effect with
a significant reduction in myocardial MDA and elevation in SOD,
CAT and GSH levels in treated diabetic group compared to diabetic
control one.5. Discussion
Diabetes mellitus is an important and prevalent risk factor for
congestive heart failure, there is a large subset of diabetic patients
with underlying cardiovascular morbidity.38 Thus a multifactorial
approach for the management of DM addressing its microvascular
and macrovascular complications is the need of the hour. There-
fore, an anti diabetic drug with additional therapeutic benefitsagainst cardiovascular complications may be beneficial in this
group of diabetic patients.
Many studies recorded a beneficial effect of apelin in different
heart models.39,40 However its cardio protective effect in diabetes
and its different mechanisms are further wanted to be elucidated
which was the aim of this current study.
The results of the present study showed that STZ injection pro-
duced a significant weight loss, hyperglycemia, hypo insulinemia
with impaired OGTT indicated by a significant increase in AUCglu-
cose associated with a significant decrease in AUCinsulin values in
diabetic control animals as compared to normal control ones.
Increasing evidence suggested that hyperglycemia is a major
etiological factor in the development of diabetic cardiomyopathy.
It leads to abnormalities in substrate supply and utilization with
impaired lipid metabolism. Furthermore, it promotes excessive
Fig. 4. Effect of apelin-13 (100 nmol/kg/day) on left ventriclular protein content in experimental animals after 8 weeks treatment. NC = normal control group; DC = Diabetic
control group; AD = Apelin-13 treated diabetic group. Data are expressed as mean ± (SD). *At P < 0.05 versus normal control group, #at P < 0.05 versus control diabetic group.
Fig. 5. Effect of apelin-13 (100 nmol/kg/day) on left ventricular collagen content in experimental animals after 8 weeks treatment. NC = normal control group; DC = Diabetic
control group; AD = Apelin-13 treated diabetic group. Data are expressed as mean ± (SD). *At P < 0.05 versus normal control group, #at P < 0.05 versus control diabetic group.
Table 3
Effect of apelin-13 (100 nmol/kg/day) on oxidative stress related markers in hearts of









10.2 ± 0.48 4.6 ± 0.37a 8.61 ± 0.41b
Catalase (units/min/mg
protein)
11.66 ± 0.32 4.88 ± 0.31a 10.24 ± 0.49b
GSH (mg/mg protein) 30.2 ± 4.2 19.7 ± 3.2a 25.1 ± 2.28b
MDA (nmol/mg protein) 2.78 ± 0.20 4.47 ± 0.25a 3.06 ± 0.25b
Superoxide dismutase (SOD), Malondialdehyde (MDA), Reduced glutathione (GSH).
All values are expressed as Mean ± SD of 10 rats in each group.
a P < 0.05 versus normal control group.
b P < 0.05 versus diabetic control group.
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mal gene expression, faulty signal transduction, and cardiomy-
ocytes apoptosis.41
Furthermore, it was suggested that altered glucose supply and
utilization by cardiac myocytes could be the primary injury inthe pathogenesis of this specific heart muscle disease. Therefore,
it is necessary to increase glucose utilization or increase the rate
of glucose transport in the diabetic heart to improve its function.1
It was observed in this current study that apelin treatment sig-
nificantly decreased serum glucose level without concomittent
change in insulin output, Furthermore, it significantly attenuated
STZ-induced increase in AUC glucose but did not alter the AUC
insulin value.
These data collectively indicated that apelin has the ability to
produce a glucose lowering effect through a most likely insulin-
independent manner which may be due to its ability to increase
glucose utilization. As many studies showed that apelin increased
glucose utilization by different tissues as skeletal muscle, adipose
tissue and myocardial muscle and this was suggested to be medi-
ated through a pathway involving adenosine mono phosphate
kinase (AMPK).12,42,43
In addition, hemodynamic factors may be associated with
increased glucose utilization under apelin treatment, as it was sug-
gested that vasodilatation is associated with increased glucose uti-
lization, whereas vasoconstriction results in decreased glucose
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dependent vasodilatation by triggering the release of nitric oxide
(NO) which increased glucose utilization by tissues.12
Despite the insignificant effect of apelin treatment on insulin
secretion in this study, apelin recorded some beneficial effects on
beta cells of the pancreas of Akita mice (a well-established type I
diabetic model) by reducing endoplasmic reticulum stress of pan-
creatic cells which leads to modification of pancreatic islet mass
reduction and preservation of insulin content.44
As regarding apelin’s effect on lipid profile that represent an
important issue in management of diabetes and its associated car-
diac changes, this current study recorded an increased level of
triglycerides and total cholesterol in STZ diabetic rats while HDL-
cholesterol levels were significantly lower. These results were
improved by apelin treatment proving its anti hyperlipidemic
effect.
Earlier studies have shown that in STZ-diabetic rats, hyper-
glycemia is associated with hypercholesterolemia and hyper-
triglyceridemia which play a key role in the pathogenesis of
diabetic cardiomyopathy and that the rate of free fatty acid (FFA)
uptake by myocardium is inversely proportional to the severity
of the myocardial dysfunction.1 Thus reducing the serum lipid
levels through dietary or drug therapy decreases the risk of cardio-
vascular disease and its related cardiovascular complications.45
The elevated circulating FFA produces inhibition of glucose oxi-
dation, abnormal high oxygen requirements during FFA metabo-
lism and the intracellular accumulation of potentially toxic
intermediates of FFA, all of which lead to impaired myocardial per-
formance and severe morphological changes. Thus, strategy to be
employed to produce improvement in cardiac function is to
improve upon these metabolic disarrangements.6
Apelin’s ability to improve lipid metabolism and to decrease
FFA release is attributed to its dual inhibition on both adipogenesis
and lipolysis; as apelin suppresses adipogenesis through adeno-
sine monophosphate protein kinase (MAPK) dependent pathways,
while it inhibits lipolysis by preventing lipid droplet fragmenta-
tion by increasing the amount of perilipin surrounding the lipid
vacuoles, giving them a greater stability and a resistance to
lipases.46
According to the results of this study, STZ - induced diabetes
evoked a deleterious effect on heart indicated by high serum LDH
and CK-MB activity level in STZ diabetic rats compared to normal
control ones and this was attenuated by apelin treatment.
It was claimed that abnormally high activity of serum LDH and
CK-MB is a specific and extremely sensitive index of myocardial
damage, necrosis or ischemia.47
Increased cardiac enzymes level in diabetes was also recorded
in the study of Fuleshwor et al.48 indicating myocardial damage
and atherosclerosis was referred to be one of the contributing
factors of this damage, as it leads to deposition of cholesterol and
cholesterol esters, that cause narrowing of the coronary artery with
subsequent decrease in the necessary nutrients to the heart affect-
ing its function. Apelin may limit atherosclerosis progression by
promoting intracellular cholesterol efflux and reducing macro-
phage foam cell formation thus improving the cardiac function in
diabetic patients.49
Also the decrease in serum levels of LDH and CK-MB under ape-
lin treatment was recorded in myocardial infarction (MI) model50
which was mediated by its ability to decrease lipid peroxidation
and enhancement of No production. Hyperglycemia also increased
oxidative stress and reduced NO bioavailability which resulted in
endothelial cell dysfunction in the vasculature of diabetic heart
with subsequent cardiac tissue injury and elevated serum cardiac
enzymes level,51 this was attenuated by apelin explaining its
cardioprotective effect in diabetic cardiomyopathy.The results of this current study revealed that, the cardiac and
left hypertrophy indicies together with LV protein and collagen
contents were increased in diabetic hearts and decreased signifi-
cantly under apelin treatment.
These findings are consistent with the published data by Wang
et al.52 who reported that STZ-induced diabetic rats exhibited car-
diac hypertrophy after 8 weeks of diabetes induction. Furthermore
echocardiographic evidence revealed that LVH is a common struc-
tural and functional alternation in diabetic patients even in the
absence of coronary artery disease or hypertension and may con-
tribute to reduced myocardial compliance.3
Also, Poornima et al.53 recorded that myocardial fibrosis and
myocyte hypertrophy are the most frequently proposed mecha-
nisms to explain cardiac changes in diabetic cardiomyopathy, as
increased collagen formation and accumulation of protein within
the interstitium lead to cardiac wall stiffness and fibrosis which
result in cardiac dysfunction.38
The diabetic heart is metabolically characterized by increased
fatty acid oxidation, leading to lipid accumulation in the myocar-
dium with subsequent cardiac hypertrophy.54 Thus the beneficial
effect of apelin in ameliorating this diabetes-induced cardiac
hypertrophy could be directly attributable to its anti hyperlipi-
demic effect as mentioned above.
In addition, previous studies showed that the increased fibrous
tissue formation and accumulation of collagen in STZ diabetes
cause LVH, and this is may be due to impaired collagen degradation
resulting from glycosylation of the lysine residues on collagen, sug-
gesting that good diabetic control is associated with the improve-
ment of LV hypertrophy6 which was provided by apelin through its
hypoglycemic effect.
Furthermore, apelin’s ability to decrease collagen and fibrous
tissue formation may be attributed to its inhibition to transforming
growth factor-Beta (TGF-b) and this is mediated through a sphin-
gosine kinase 1 (SphK1) dependant mechanism.55 TGF-b is a cyto-
kine that has a key role in mediating expression and differentiation
of fibroblasts into myofibroblasts and this process is a key event in
the progression of cardiac fibrosis, and it was recorded that TGF-b
gene expression is enhanced by diabetes and thus, its inhibition
has a beneficial role in decreasing cardiac fibrosis and stiffness.56
Also, its ability to decrease myocardial fibrosis may be
explained by its anti-inflammatory properities, as it has the ability
to suppress effectively the expression of inflammatory cytokines
such as tumor necrosis factor alpha (TNF-a) and interleukin (IL)-
1b protein.57 These cytokines trigger a chronic inflammatory pro-
cess and cell injury in the heart ultimately inducing cardiac fibrosis
as a consequence, thus suppression of these cytokines have been
shown to reduce cardiac fibrosis, and enhance cardiac function.58
It was obvious from the present investigation that, the level of
myocardial SOD, GSH, and catalase enzymes were decreased, while
MDA was increased on STZ induction, all of which was improved
by apelin treatment indicating its antioxidant properties.
Yosuke et al.3 concluded that hyperglycemia and metabolic
abnormalities of diabetes lead to production of reactive oxygen
species (ROS) which plays a pivotal role in the development of
diabetes-induced cardiovascular disease. Increased ROS generation
causes activation of maladaptive signaling pathways with subse-
quent cell death and abnormal cardiac remodeling which lead to
the characteristic morphological and functional abnormalities
associated with diabetic cardiomyopathy. Thus, strategies that
either reduce ROS or augment myocardial antioxidant defense
mechanisms might have therapeutic efficacy in improving myocar-
dial function in diabetes mellitus.59
Improvement of myocardial antioxidants enzymes and
decreased MDA under apelin treatment had been recorded previ-
ously in myocardial I/R injury.60
126 I.I. Hegab / Alexandria Journal of Medicine 54 (2018) 119–127The antioxidant effect of apelin is mediated through its upregu-
lation to the cardiac antioxidant enzymes by increasing their
mRNA expression, also apelin has the ability to decrease excessive
mitochondrial ROS production with subsequent preservation of
myocardial metabolic status in cardiomyocytes. In addition, Zhang
et al.61 suggested that apelin could suppress ROS generation by
down-regulation of inducible nitric oxide synthase expression
which improved myocardial injury.
6. In conclusion
The results of this study had clearly demonstrated that apelin
protected against STZ induced metabolic abnormalities and its
associated cardiac changes. Thus diabetics, who have an increased
risk of cardiac dysfunction, may benefit both from an improvement
in glucose and lipid homeostasis as well as from the antioxidant
and cardioprotective effects of apelin.
Assuming that these animal studies can be extended to humans,
apelin may be useful as an adjunct therapy with oral hypoglycemic
agents in the management of diabetes mellitus and its cardiac
complications.
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